184 related articles for article (PubMed ID: 35381444)
21. Expression patterns and clinical implications of PDL1 and DLL3 biomarkers in small cell lung cancer retrospectively studied: Insights for therapeutic strategies and survival prediction.
Domvri K; Yaremenko AV; Apostolopoulos A; Petanidis S; Karachrysafi S; Pastelli N; Papamitsou T; Papaemmanouil S; Lampaki S; Porpodis K
Heliyon; 2024 Mar; 10(5):e27208. PubMed ID: 38468968
[TBL] [Abstract][Full Text] [Related]
22. Mutational landscape of homologous recombination-related genes in small-cell lung cancer.
Wu S; Zhang Y; Zhang Y; Chen LH; Ouyang HF; Xu X; Du Y; Ti XY
Cancer Med; 2023 Feb; 12(4):4486-4495. PubMed ID: 36053931
[TBL] [Abstract][Full Text] [Related]
23. DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy.
Su PL; Chakravarthy K; Furuya N; Brownstein J; Yu J; Long M; Carbone D; Li Z; He K
Mol Cancer; 2024 May; 23(1):97. PubMed ID: 38730427
[TBL] [Abstract][Full Text] [Related]
24. CAR NK-92 cells targeting DLL3 kill effectively small cell lung cancer cells in vitro and in vivo.
Liu M; Huang W; Guo Y; Zhou Y; Zhi C; Chen J; Li J; He J; Lian H; Zhou J; Ye X; Hu Y; Hu H; Liu Z; Huang J; Lin L; Cai M; Wang X; Huang J; Zhang Z; Zhu K; Zhao Q; Cao B
J Leukoc Biol; 2022 Oct; 112(4):901-911. PubMed ID: 35088475
[TBL] [Abstract][Full Text] [Related]
25. Potential prognostic value of delta-like protein 3 in small cell lung cancer: a meta-analysis.
Chen B; Li H; Liu C; Wang S; Zhang F; Zhang L; Li M; Li G
World J Surg Oncol; 2020 Aug; 18(1):226. PubMed ID: 32847588
[TBL] [Abstract][Full Text] [Related]
26. The prognostic implications of Notch1, Hes1, Ascl1, and DLL3 protein expression in SCLC patients receiving platinum-based chemotherapy.
Tendler S; Kanter L; Lewensohn R; Ortiz-Villalón C; Viktorsson K; De Petris L
PLoS One; 2020; 15(10):e0240973. PubMed ID: 33104707
[TBL] [Abstract][Full Text] [Related]
27. Delta-like Protein 3 Prevalence in Small Cell Lung Cancer and DLL3 (SP347) Assay Characteristics.
Huang RSP; Holmes BF; Powell C; Marati RV; Tyree D; Admire B; Streator A; Newell AEH; Perez J; Dalvi D; ElGabry EA
Arch Pathol Lab Med; 2019 Nov; 143(11):1373-1377. PubMed ID: 30958693
[TBL] [Abstract][Full Text] [Related]
28. Unravelling the biology of SCLC: implications for therapy.
Sabari JK; Lok BH; Laird JH; Poirier JT; Rudin CM
Nat Rev Clin Oncol; 2017 Sep; 14(9):549-561. PubMed ID: 28534531
[TBL] [Abstract][Full Text] [Related]
29. PD-L1 Expression in Small Cell and Large Cell Neuroendocrine Carcinomas of Lung: an Immunohistochemical Study with Review of Literature.
Guleria P; Kumar S; Malik PS; Jain D
Pathol Oncol Res; 2020 Oct; 26(4):2363-2370. PubMed ID: 32506394
[TBL] [Abstract][Full Text] [Related]
30. Characterization of DLL3-positive circulating tumor cells (CTCs) in patients with small cell lung cancer (SCLC) and evaluation of their clinical relevance during front-line treatment.
Messaritakis I; Nikolaou M; Koinis F; Politaki E; Koutsopoulos A; Lagoudaki E; Vetsika EK; Georgoulias V; Kotsakis A
Lung Cancer; 2019 Sep; 135():33-39. PubMed ID: 31447000
[TBL] [Abstract][Full Text] [Related]
31. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer.
Rudin CM; Reck M; Johnson ML; Blackhall F; Hann CL; Yang JC; Bailis JM; Bebb G; Goldrick A; Umejiego J; Paz-Ares L
J Hematol Oncol; 2023 Jun; 16(1):66. PubMed ID: 37355629
[TBL] [Abstract][Full Text] [Related]
32. Influence of preanalytical variables on performance of delta-like protein 3 (DLL3) predictive immunohistochemistry.
Radonic T; Duin S; Vos W; Kortman P; Zwinderman AH; Thunnissen E
Virchows Arch; 2021 Feb; 478(2):293-300. PubMed ID: 32488689
[TBL] [Abstract][Full Text] [Related]
33. Identification of candidate responders for anti-PD-L1/PD-1 immunotherapy, Rova-T therapy, or EZH2 inhibitory therapy in small-cell lung cancer.
Saito M; Saito K; Shiraishi K; Maeda D; Suzuki H; Minamiya Y; Kono K; Kohno T; Goto A
Mol Clin Oncol; 2018 Feb; 8(2):310-314. PubMed ID: 29435295
[TBL] [Abstract][Full Text] [Related]
34. Notch inhibition by the ligand DELTA-LIKE 3 defines the mechanism of abnormal vertebral segmentation in spondylocostal dysostosis.
Chapman G; Sparrow DB; Kremmer E; Dunwoodie SL
Hum Mol Genet; 2011 Mar; 20(5):905-16. PubMed ID: 21147753
[TBL] [Abstract][Full Text] [Related]
35. High PD-L1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers.
Chang YL; Yang CY; Huang YL; Wu CT; Yang PC
Oncotarget; 2017 Mar; 8(11):18021-18030. PubMed ID: 28152514
[TBL] [Abstract][Full Text] [Related]
36. Delta-like ligand 3 (DLL3): an attractive actionable target in tumors with neuroendocrine origin.
Ranallo N; Bocchini M; Menis J; Pilotto S; Severi S; Liverani C; Bongiovanni A
Expert Rev Anticancer Ther; 2022 Jun; 22(6):597-603. PubMed ID: 35477310
[TBL] [Abstract][Full Text] [Related]
37. Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC).
Berghoff AS; Ricken G; Wilhelm D; Rajky O; Widhalm G; Dieckmann K; Birner P; Bartsch R; Preusser M
J Neurooncol; 2016 Oct; 130(1):19-29. PubMed ID: 27436101
[TBL] [Abstract][Full Text] [Related]
38. Development of targeted therapy and immunotherapy for treatment of small cell lung cancer.
Saito M; Shiraishi K; Goto A; Suzuki H; Kohno T; Kono K
Jpn J Clin Oncol; 2018 Jul; 48(7):603-608. PubMed ID: 29762727
[TBL] [Abstract][Full Text] [Related]
39. DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile.
Hermans BCM; Derks JL; Thunnissen E; van Suylen RJ; den Bakker MA; Groen HJM; Smit EF; Damhuis RA; van den Broek EC; ; Ruland A; Speel EJM; Dingemans AMC
Lung Cancer; 2019 Dec; 138():102-108. PubMed ID: 31678831
[TBL] [Abstract][Full Text] [Related]
40. Small cell lung cancer, an epithelial to mesenchymal transition (EMT)-like cancer: significance of inactive Notch signaling and expression of achaete-scute complex homologue 1.
Ito T; Kudoh S; Ichimura T; Fujino K; Hassan WA; Udaka N
Hum Cell; 2017 Jan; 30(1):1-10. PubMed ID: 27785690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
